Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

Dedifferentiation state has been associated with therapy resistance in melanoma. Here, the authors uncover a pre-existing NGFR-expressing, targetable subpopulation that is resistant to immunotherapy and other treatments in melanoma cells and preclinical models.

Guardado en:

Detalles Bibliográficos
Autores principales:	Julia Boshuizen, David W. Vredevoogd, Oscar Krijgsman, Maarten A. Ligtenberg, Stephanie Blankenstein, Beaunelle de Bruijn, Dennie T. Frederick, Juliana C. N. Kenski, Mara Parren, Marieke Brüggemann, Max F. Madu, Elisa A. Rozeman, Ji-Ying Song, Hugo M. Horlings, Christian U. Blank, Alexander C. J. van Akkooi, Keith T. Flaherty, Genevieve M. Boland, Daniel S. Peeper
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/0aa2077077d243cb9f117c28a0c8e4f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0aa2077077d243cb9f117c28a0c8e4f1
record_format	dspace
spelling	oai:doaj.org-article:0aa2077077d243cb9f117c28a0c8e4f12021-12-02T16:35:46ZReversal of pre-existing NGFR-driven tumor and immune therapy resistance10.1038/s41467-020-17739-82041-1723https://doaj.org/article/0aa2077077d243cb9f117c28a0c8e4f12020-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-17739-8https://doaj.org/toc/2041-1723Dedifferentiation state has been associated with therapy resistance in melanoma. Here, the authors uncover a pre-existing NGFR-expressing, targetable subpopulation that is resistant to immunotherapy and other treatments in melanoma cells and preclinical models.Julia BoshuizenDavid W. VredevoogdOscar KrijgsmanMaarten A. LigtenbergStephanie BlankensteinBeaunelle de BruijnDennie T. FrederickJuliana C. N. KenskiMara ParrenMarieke BrüggemannMax F. MaduElisa A. RozemanJi-Ying SongHugo M. HorlingsChristian U. BlankAlexander C. J. van AkkooiKeith T. FlahertyGenevieve M. BolandDaniel S. PeeperNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Julia Boshuizen David W. Vredevoogd Oscar Krijgsman Maarten A. Ligtenberg Stephanie Blankenstein Beaunelle de Bruijn Dennie T. Frederick Juliana C. N. Kenski Mara Parren Marieke Brüggemann Max F. Madu Elisa A. Rozeman Ji-Ying Song Hugo M. Horlings Christian U. Blank Alexander C. J. van Akkooi Keith T. Flaherty Genevieve M. Boland Daniel S. Peeper Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
description	Dedifferentiation state has been associated with therapy resistance in melanoma. Here, the authors uncover a pre-existing NGFR-expressing, targetable subpopulation that is resistant to immunotherapy and other treatments in melanoma cells and preclinical models.
format	article
author	Julia Boshuizen David W. Vredevoogd Oscar Krijgsman Maarten A. Ligtenberg Stephanie Blankenstein Beaunelle de Bruijn Dennie T. Frederick Juliana C. N. Kenski Mara Parren Marieke Brüggemann Max F. Madu Elisa A. Rozeman Ji-Ying Song Hugo M. Horlings Christian U. Blank Alexander C. J. van Akkooi Keith T. Flaherty Genevieve M. Boland Daniel S. Peeper
author_facet	Julia Boshuizen David W. Vredevoogd Oscar Krijgsman Maarten A. Ligtenberg Stephanie Blankenstein Beaunelle de Bruijn Dennie T. Frederick Juliana C. N. Kenski Mara Parren Marieke Brüggemann Max F. Madu Elisa A. Rozeman Ji-Ying Song Hugo M. Horlings Christian U. Blank Alexander C. J. van Akkooi Keith T. Flaherty Genevieve M. Boland Daniel S. Peeper
author_sort	Julia Boshuizen
title	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
title_short	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
title_full	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
title_fullStr	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
title_full_unstemmed	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
title_sort	reversal of pre-existing ngfr-driven tumor and immune therapy resistance
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/0aa2077077d243cb9f117c28a0c8e4f1
work_keys_str_mv	AT juliaboshuizen reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT davidwvredevoogd reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT oscarkrijgsman reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT maartenaligtenberg reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT stephanieblankenstein reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT beaunelledebruijn reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT dennietfrederick reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT julianacnkenski reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT maraparren reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT mariekebruggemann reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT maxfmadu reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT elisaarozeman reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT jiyingsong reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT hugomhorlings reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT christianublank reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT alexandercjvanakkooi reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT keithtflaherty reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT genevievemboland reversalofpreexistingngfrdriventumorandimmunetherapyresistance AT danielspeeper reversalofpreexistingngfrdriventumorandimmunetherapyresistance
_version_	1718383674958807040

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

Ejemplares similares